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A B S T R A C T
Background
Aortic valve stenosis is the most common type of valvular heart disease in the USA and Europe. Aortic valve stenosis is considered
similar to atherosclerotic disease. Some studies have evaluated statins for aortic valve stenosis.
Objectives
To evaluate the effectiveness and safety of statins in aortic valve stenosis.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS - IBECS,Web of Science
and CINAHL Plus. These databases were searched from their inception to 24 November 2015. We also searched trials in registers for
ongoing trials. We used no language restrictions.
Selection criteria
Randomised controlled clinical trials (RCTs) comparing statins alone or in association with other systemic drugs to reduce cholesterol
levels versus placebo or usual care.
Data collection and analysis
Primary outcomes were severity of aortic valve stenosis (evaluated by echocardiographic criteria: mean pressure gradient, valve area and
aortic jet velocity), freedom from valve replacement and death from cardiovascular cause. Secondary outcomes were hospitalisation for
any reason, overall mortality, adverse events and patient quality of life.
Two review authors independently selected trials for inclusion, extracted data and assessed the risk of bias. The GRADE methodology
was employed to assess the quality of result findings and the GRADE profiler (GRADEPRO) was used to import data from Review
Manager 5.3 to create a ’Summary of findings’ table.
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Main results
We included four RCTs with 2360 participants comparing statins (1185 participants) with placebo (1175 participants). We found
low-quality evidence for our primary outcome of severity of aortic valve stenosis, evaluated by mean pressure gradient (mean difference
(MD) -0.54, 95% confidence interval (CI) -1.88 to 0.80; participants = 1935; studies = 2), valve area (MD -0.07, 95% CI -0.28
to 0.14; participants = 127; studies = 2), and aortic jet velocity (MD -0.06, 95% CI -0.26 to 0.14; participants = 155; study = 1).
Moderate-quality evidence showed no effect on freedom from valve replacement with statins (risk ratio (RR) 0.93, 95%CI 0.81 to 1.06;
participants = 2360; studies = 4), and no effect on muscle pain as an adverse event (RR 0.91, 95% CI 0.75 to 1.09; participants = 2204;
studies = 3; moderate-quality evidence). Low- and very low-quality evidence showed uncertainty around the effect of statins on death
from cardiovascular cause (RR 0.80, 95% CI 0.56 to 1.15; participants = 2297; studies = 3; low-quality evidence) and hospitalisation
for any reason (RR 0.84, 95% CI 0.39 to 1.84; participants = 155; study = 1; very low-quality evidence). None of the four included
studies reported on overall mortality and patient quality of life.
Authors’ conclusions
Result findings showed uncertainty surrounding the effect of statins for aortic valve stenosis.The quality of evidence from the reported
outcomes ranged frommoderate to very low. These results give support to European and USA guidelines (2012 and 2014, respectively)
that so far there is no clinical treatment option for aortic valve stenosis.
P L A I N L A N G U A G E S U M M A R Y
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Review question
What is the evidence regarding the effect of statins in people suffering from aortic valve stenosis?
Background
The heart is responsible for pumping blood throughout the body. It has four valves that control the blood flow within it. One of the
valves is the aortic valve that controls the flow of blood from the left ventricle chamber to the body. Aortic valve stenosis is a disease
characterised by the narrowing of this valve. This is the most common type of valvular heart disease in the USA and Europe. Its
incidence rises with age and 2% to 7% of adults over 65 years old have aortic valve stenosis. Aortic valve stenosis is considered similar to
atherosclerotic disease and it is known to have a long asymptomatic period for several decades. When it manifests clinically, symptoms
such as syncope (brief lapse of consciousness), angina and dyspnoea (shortness of breath) may lead to death. Some prospective and
retrospective trials have shown that statins can delay the progression of aortic valve stenosis. Statins are considered very useful drugs to
lower high cholesterol.
Study characteristics
The evidence is current up to 24November 2015.We searched electronic databases for reports of randomised controlled trials comparing
statins alone or in combination with other types of lipid-lowering drugs in the treatment of aortic valve stenosis.
Key results
We evaluated the severity of aortic valve stenosis according to the following echocardiographic criteria: mean pressure gradient, valve
area and aortic jet velocity. We also evaluated freedom from valve replacement and death from cardiovascular cause. There were no
differences in effect for mean pressure gradient, valve area, freedom from valve replacement and death from cardiovascular cause in
the statin group when compared with the placebo group. We were not able to conduct a meta-analysis to assess the aortic jet velocity
as only one study analysed this outcome. We also checked the safety of statins by analysing other adverse events among them muscle
pain. Muscle pain is the most prevalent adverse event that can limit the use of statin. Muscle pain did not differ in the statin group
when compared with the placebo group. Results of four randomised controlled trials with 2360 participants showed that statins did
not delay the progression of aortic valve stenosis.
Quality of evidence
The quality of the evidence quality ranged frommoderate to very low across the different outcomes due to the limitations of the original
studies. Included studies had at least one methodological limitation.
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Conclusions
Based on the evidence in this review, there is uncertainty surrounding the effect of statins for aortic valve stenosis. These results give
support to European and USA guidelines (2012 and 2014, respectively) that so far there is no clinical treatment option for aortic
valve stenosis. An alternative might be to broaden the knowledge of the pathophysiology of this disease and include risk factors such as
calcium, heredity, vitamin D, inflammation, oxidative stress, diabetes, hypertension among others that could contribute to aortic valve
stenosis. High-quality randomised trials to include risk factors for aortic valve stenosis are needed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Statin versus Placebo for aortic valve stenosis
Patient or population: pat ients with aort ic valve stenosis
Settings: Outpat ients and hospitalisat ion
Intervention: Stat in versus Placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo Statin
Mean pressure gradient
(mmHg)
Better indicated by lower
scores.
Follow-up: median 2.4 to 4.
5 years
The mean mean pressure
gradient in the control
groups was
34 to 35 mmHg
The mean mean pressure
gradient in the intervent ion
groups was
0.54 lower
(1.88 lower to 0.8 higher)
MD -0.54 (-1.88 to 0.80) 1935
(2 studies)
⊕⊕©©
low1,2
Valve area (cm2)
Better indicated by higher
scores.
Follow-up: median 2.4- to 3.
5 years
The mean valve area in the
control groups was
1 to 1.5 cm2
The mean valve area in the
intervent ion groups was
0.07 lower
(0.28 lower to 0.14 higher)
MD -0.07 (-0.28 to 0.14) 127
(2 studies)
⊕⊕©©
low2,3
Aortic jet velocity (m/s)
Follow-up: median 2.1 years
The mean aort ic jet velocity
in the control groups was
3.45 m per second
The mean aort ic jet velocity
in the intervent ion groups
was
0.06 lower
(0.26 lower to 0.14 higher)
MD -0.06 (-0.26 to 0.14) 155
(1 study)
⊕⊕©©
low2, 3
Freedom from valve re-
placement
Follow-up: median 2.1 to 4.
5 years
Study population RR 0.93
(0.81 to 1.06)
2360
(4 studies)
⊕⊕⊕©
moderate2
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281 per 1000 261 per 1000
(227 to 298)
Moderate population
222 per 1000 206 per 1000
(180 to 235)
Death from cardiovascular
cause
Follow-up: median 2.1 to 4.
5 years
Study population RR 0.80
(0.56 to 1.15)
2297
(3 studies)
⊕⊕©©
low2,4
56 per 1000 45 per 1000
(31 to 64)
Moderate population
39 per 1000 31 per 1000
(22 to 45)
Hospitalisation for any rea-
son
Follow-up: median 2.1 years
154 per 1000 129 per 1000
(60 to 283)
RR 0.84
(0.39 to 1.84)
155
(1 study)
⊕©©©
very low2,3,4
Adverse events - Muscle
pain
Follow-up: median 2.4 to 4.
5 years
Study population RR 0.91
(0.75 to 1.09)
2204
(3 studies)
⊕⊕⊕©
moderate2
168 per 1000 153 per 1000
(126 to 183)
Moderate population
30 per 1000 27 per 1000
(22 to 33)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded by one due to randomisat ion and allocat ion being unclear for Rossebø 2008.
2 Downgraded by one due to possible risk of publicat ion bias as only a small number of studies were ident if ied.
3 Downgraded by one due to imprecision: small sample size with ef fect size crossing the line of no ef fect.
4 Downgraded by one due to imprecision: very few events < 300.
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B A C K G R O U N D
Aortic valve stenosis is themain type of heart valve disease observed
in high-income countries.Calcified aortic stenosis is the main eti-
ology of this disease. There are two more causes of aortic valve
stenosis, namely congenital and rheumatic diseases (Vahanian
2012). Currently, aortic valve stenosis is the most common indi-
cation for surgical valve replacement in North America and Eu-
rope (Vahanian 2010). The number of cases of aortic valve re-
placements has doubled in the past decade in the USA, due to the
ageing population (Dweck 2012). When aortic valve replacement
is combined with bypass surgery, operative mortality ranges from
5% to 7% (Vahanian 2010). In the last few years, transcatheter
aortic valve implantation (TAVI) has been used as an alternative
for patients with contraindications to surgery or for high-risk pa-
tients (Vahanian 2012).
Description of the condition
Aortic valve stenosis is the most prevalent valve illness in adults
and the third cause of cardiovascular disorders (after arterial hyper-
tension and coronary artery disease) (Parolari 2011). Aortic valve
stenosis is characterised by a reduction of the aortic valve area, and
it ismainly caused by the calcification of its three leaflets (Vahanian
2012). These leaflets are the part of the aortic valve designed to
open in the direction of the blood flow. The incidence of aortic
valve stenosis ranges from 2% to 7% in adults over 65 years old
(Vahanian 2012). This calcification process is known to be con-
stant and is evidenced by lipid deposition, inflammation and the
accumulation of calcium, and is similar to coronary atherosclerosis
in many aspects (Dweck 2012). Other causes of aortic valve steno-
sis, with varying prevalence rates in different populations, include
bicuspid aortic valve and rheumatic disease. Patients with bicuspid
aortic valve have shown a higher tendency to have calcification
than patients with tricuspid aortic valve. Bicuspid aortic valve is
more common in younger adults and its incidence ranges from
0.5% to 2.0% in the population (Siu 2010). Rheumatic disease
remains an important public health problem in low- and middle-
income countries with a prevalence of around 1% among school
children in Africa, Asia and Latin America (Canterin 2010). The
prevalence of aortic disease among people with rheumatic disease
in these countries ranges from 5% to 24% in the population and
its calcification process is less common (Canterin 2009). Aortic
valve stenosis is a progressive disease which may last for decades,
and which causes obstruction of the left ventricular outflow tract
leading to ventricular hypertrophy and subsequently heart fail-
ure (Dweck 2012). The onset of typical symptoms such as dysp-
noea (shortness of breath), angina and syncope (brief lapse of con-
sciousness) is closely related to the severity of the illness (Vahanian
2010). The degree of valve obstruction can be assessed by Doppler
echocardiography, the gold standard for the disease, which is used
tomeasure the valve area, mean pressure gradient and aortic jet ve-
locity (Vahanian 2012; Nishimura 2014). The echocardiographic
criteria for aortic valve stenosis (Vahanian 2012, Nishimura 2014)
are shown in Table 1.
Description of the intervention
Statins are lipid-lowering drugs recommended for the treatment
of some disease such as diabetes, acute infarction myocardial and
dyslipidaemia (abnormal blood levels of cholesterol) (Stone 2014).
Randomised controlled trials (RCTs) have demonstrated the im-
portance of statins in decreasing cardiovascular events (Ridker
2008). Statins act inside the liver by blocking hydroxymethylglu-
taryl coenzyme A (HMG CoA) reductase enzyme which plays a
key role in cholesterol synthesis (Vaughan 2004; Kapur 2008).
Besides inhibiting the enzyme responsible for the formation of
cholesterol, statins have several pleiotropic effects such as nitric ox-
ide increase, endothelial function improvement, antioxidant, anti-
thrombotic and anti-inflammatory actions, atherosclerotic plaque
stabilisation and anticoagulant action (Kapur 2008). Most peo-
ple have shown good tolerance to statins. However, adverse effects
such as liver dysfunction and myopathy may occur. Muscle pain is
the main symptom of myopathy that can limit the use of statins.
It occurs in 1.5 % to 5% of patients treated with statins (Mancini
2011). A recent systematic review (Macedo 2014) regarding the
safety of statins in 86 included studies demonstrated the presence
of the following adverse effects: myopathy, liver enzymes and dia-
betes (respectively: odds ratio (OR) 2.63 [95% confidence interval
(CI) 1.50 to 4.61]; OR 1.54 [95% CI 1.47 to 1.62]; OR 1.31
[95% CI 0.99 to 1.73]). However, the review considered them
minor adverse effects when compared with the beneficial effects
of statins in major cardiovascular events (Macedo 2014).
How the intervention might work
Calcified aortic valve stenosis has recently come to be considered
an active and progressive inflammatory process, and similar to
coronary atherosclerosis in many aspects (Dweck 2012).What oc-
curs is a build-up of fat on the valve leaflets promoting oxidation
of low-density lipoprotein (LDL) by macrophages, activation of
myofibroblasts, infiltration of T lymphocytes and cell prolifera-
tion from pro-inflammatory cytokines IL 1(beta), as well as tu-
mour necrosis factor (TNF alpha) (Liebe 2006). Considering the
possible relationship between aortic valve stenosis and atheroscle-
rotic disease, statins may halt the progression, or even induce re-
gression of aortic valve stenosis by inhibiting HMG-CoA reduc-
tase, which decreases fat deposition on the valve leaflets (Pedersen
2008). Statins also have anti-inflammatory actions such as reduc-
ing cytokines, blocking smooth muscle cell and T cell depletion,
as well as blocking macrophage-oxidised LDL which hinders foam
cells formation (Liebe 2006; Dweck 2012). Studies to verify the
possible benefit of statins for the treatment of aortic valve steno-
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sis have already been conducted. A retrospective non-randomised
observational study with the lowest level of evidence showed that
statin therapy was successful in delaying the progression of aortic
valve stenosis based on a slow reduction in the valve area (P =
0.02) and a small increase in peak pressure gradient (P = 0.01)
(Novaro 2001; Pedersen 2008). Other randomised control trials
(SALTIRE, SEAS, ASTRONOMER) have also evaluated the role
of various statins in halting the progression of aortic valve stenosis
over the past 10 years (Cowell 2005; Rossebø 2008; Chan 2010).
The SALTIRE study (A randomised trial of intensive lipid-low-
ering therapy in calcific aortic stenosis, Cowell 2005) evaluated
the effect of 80 mg of atorvastatin in the progression of aortic
valve stenosis. A total of 155 patients (mostly men) with a mean
age of 68 years were included. The trial did not show any benefit
of atorvastatin to slow the progression and calcification of aortic
valve stenosis (P = 0.93) (Cowell 2005). The SEAS trial (Intensive
lipid lowering with simvastatin and ezetimibe in aortic stenosis,
Rossebø 2008) evaluated the effect of the association of 40 mg
of simvastatin plus 10 mg of ezetimibe in 1873 patients (mostly
men) with mild to moderate aortic valve stenosis and a mean age
of 67 years (Rossebø 2008). The conclusion of this trial was that
simvastatin plus ezetimibe did not reduce the progression of aortic
valve stenosis (P = 0.77). The ASTRONOMER trial (Effect of
lipid lowering with rosuvastatin on progression of aortic stenosis,
Chan 2010) evaluated the effect of 40 mg of rosuvastatin in 269
patients (mostly men) with mild to moderate aortic stenosis and a
mean age 58 years. There were no significant differences between
the two groups (rosuvastatin versus placebo) in the progression
of the disease (mean pressure gradient and aortic valve area) (P =
0.32), cardiovascular death and the need for aortic valve replace-
ment (P = 0.446), as well as adverse events (P = 0.64) (Chan 2010).
Currently, there is no recommended dosage of statins to treat aor-
tic valve stenosis (Vahanian 2012; Nishimura 2014).
Why it is important to do this review
The current evidence shows there is still no effective clinical treat-
ment to halt the progression of aortic valve stenosis (Cowell 2005,
Rossebø 2008, Chan 2010, Van der Linde 2011). Many patients
with aortic valve stenosis who are eventually submitted to invasive
procedures such as valve replacement are often diagnosed in the
advanced stages of the disease (Katz 2010). Many of these patients
also suffer from common chronic diseases such as diabetes, hyper-
tension, dyslipidaemia, as well as the risks associated with smoking
(Rajamannan 2008), which hinder post-operative recovery. They
are also subjected to long periods of hospitalisation which repre-
sents high costs for health services. Therefore, in order to promote
a new rational decision-making process regarding clinical inter-
ventions such as statins for the treatment of aortic valve stenosis,
we proposed a systematic review of randomised controlled trials
(Mulrow 1994) using Cochrane criteria (Higgins 2011). This re-
view is important as it uses the best available evidence to assess
the effects of statins on the progression of aortic valve stenosis,
thus limiting the risk of systematic and random errors in the anal-
yses and providing credible results (Antman 1992; Oxman1993;
Higgins 2011).
O B J E C T I V E S
General objective
To evaluate the effectiveness and safety of statins in aortic valve
stenosis.
Specific objectives
1. To evaluate the effectiveness of statins in the following
subgroups: mild aortic valve stenosis, moderate aortic valve
stenosis and severe aortic valve stenosis.
2. To investigate the safety of statins in aortic valve stenosis by
analysing the adverse effects observed in the included studies.
3. To assess the quality of life of patients suffering from aortic
valve stenosis and undergoing treatment with statins.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published or ongoing randomised controlled clinical trials (RCTs)
inwhich statins alone or in associationwith other systemic drugs to
reduce cholesterol levels compared with placebo or control groups
were eligible for inclusion. We considered studies with at least one-
year follow-up.
Types of participants
Adults (age ranged 18 to 85 years) of both sexes suffering from aor-
tic valve stenosis and diagnosed by means of clinical and echocar-
diographic criteria. For more details, see Table 1. We considered
only patients with tricuspid and bicuspid aortic valve disease. We
excluded rare causes of valve disease and rheumatic disease.
Types of interventions
Statins alone or in association with other systemic drugs to reduce
cholesterol levels versus placebo or control groups.
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Types of outcome measures
Primary outcomes
• Severity of aortic valve stenosis (evaluated by
echocardiographic criteria such as mean pressure gradient, valve
area and aortic jet velocity)
• Freedom from valve replacement
• Death from cardiovascular cause
Secondary outcomes
• Hospitalisation for any reason
• Overall mortality
• Adverse events
• Patient quality of life
Search methods for identification of studies
We searched for every published or ongoing randomised controlled
clinical trial in which statins, alone or in association with other sys-
temic drugs, to reduce cholesterol levels compared with placebo or
control groups (date of the search: 24 November, 2015). Searches
were conducted by Information Scientists of the Cochrane Heart
Group and the Brazilian Cochrane Center .
Electronic searches
We searched the following electronic databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL, 2015, Issue 10 2015) in the Cochrane Library.
• MEDLINE (Ovid, 1946 to 24 November, 2015).
• Embase (Embase CLASSIC and Embase Ovid, 1947 to 23
November, 2015).
• Web of Science (Thomson Reuter, 1970 to 23 November,
2015).
• CINAHL Plus (EBSCO -1937 to 24 November, 2015).
• LILACS-IBECS (1982 to 24 November, 2015).
Details of the search strategies used can be found in Appendix 1.
We used medical subject headings (MeSH) for MEDLINE. The
terms used to search MEDLINE were modified when necessary
to search the other databases listed. No language or date restric-
tions were applied to the searches. The following RCT filter was
applied toMEDLINE (OVID) and adaptations of it were used for
Embase (OVID) and Web of Science: Cochrane Highly Sensitive
Search Strategy for identifying randomised trials in MEDLINE:
sensitivity-maximising version (2008 revision) (Higgins 2011).
Searching other resources
We checked the reference lists of the included studies to ob-
tain other articles that were not found by the search strategy.
We contacted pharmaceutical companies and authors of pub-
lished articles to get relevant information. We also searched
the WHO’s International Clinical Trials Registry Platform
(ICTRP) ( http://apps.who.int/trialsearch/), ClinicalTrials.gov (
www.clinicaltrials.gov) and Current Controlled Trials Register (
www.controlled-trials.com/) to identify ongoing trials using the
terms “aortic valve stenosis” as condition and “Hydroxymethyl-
glutaryl CoA Reductases” as intervention. We searched Grey lit-
erature in OpenGrey ( System for Information on Grey Litera-
ture in Europe) ( http://www.opengrey.eu/) and materials from
international congresses of the European Society of Cardiol-
ogy ( www.escardio.org), American Heart Association ( AHA) (
www.heart.org) and American College of Cardiology ( ACC) (
www.acc.org) with analogous terms. We imposed no language re-
strictions.
Data collection and analysis
Two review authors (LT, AFTG) independently collected data us-
ing a standard form and two review authors (LT, CRM) inde-
pendently input the data into the Review Manager (RevMan 5.3)
software (RevMan 2014).
Selection of studies
Two review authors (LT,AFTG) independently selected the studies
based on a search strategy conducted in the database. Two authors
(LT, AFTG) independently identified potentially eligible studies
by reading all the titles and abstracts of the articles found. We ob-
tained the full text of relevant studies and selected studies that sat-
isfied the inclusion criteria. The CONSORT (Consolidated Stan-
dards of Reporting Trials) statement was used to identify the RCTs
when selecting the studies (Schulz 2010) and the PRISMA (Pre-
ferred Reporting Items for Systematic reviews andMeta-Analyses)
statement was applied to check and report each step of the review
process (Moher 2009). We resolved disagreements by consensus
and asked a third review author (ANA) to make a decision when
necessary. There was a high degree of agreement between the au-
thors. The excluded studies were presented and justified in a stan-
dard form. For more details, see below Characteristics of excluded
studies section.
Data extraction and management
Two review authors (LT, AFTG) independently extracted the data
from the included studies. We used a standard form to extract
the following data: study objective, study design, study place,
date, country, follow-up, participants (total number, age, gender,
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comorbidities, inclusion and exclusion criteria, losses and with-
drawals), severity of the disease, aortic valve morphology, sta-
tistical power of the study, sample size calculation, intervention
(statins, types of statins, dosage, association with other drugs to
reduce cholesterol levels, side effects, route of administration and
placebo), results (outcome measures, adverse events and risk of
bias), and funding sources.We solved any disagreement by consen-
sus involving a third author when necessary (ANA).We contacted
the authors of the studies when the extracted data were insufficient
or unclear (Higgins 2011). We summarised the extracted data in
a meta-analysis using the Review Manager (RevMan 5.3) software
(RevMan 2014).
Assessment of risk of bias in included studies
Two review authors (LT, AFTG) independently assessed the risk
of bias by applying the Cochrane Collaboration ’Risk of bias’ tool
(Higgins 2011). The differences were settled through discussion
or by resorting to a third review author (CRM or ANA). We anal-
ysed the following items associated with the risk of bias in the in-
cluded studies: random sequence generation, allocation conceal-
ment, blinding of participants, personnel and outcome assessors,
incomplete outcome data and selective outcome reporting among
other sources of bias. We classified each of these criteria as high,
low or unclear bias categories according to the Cochrane Collabo-
ration tool and compiled them in a ’Risk of bias’ graph and ’Risk
of bias’ summary.
Measures of treatment effect
We calculated the mean difference (MD) between the treatment
groups for continuous outcomes (e.g. valve area). We calculated
risk ratio (RR) in both groups for dichotomous outcomes (e.g.
death from cardiovascular cause). (Higgins 2011). All outcomes
were reported with 95% confidence intervals (CIs).
Unit of analysis issues
Cross-over trials and cluster-randomised trials were not eligible
for inclusion because the range of this review was a progressive
disease (aortic valve stenosis), and the unit of randomisation was
the individual. Four RCTs were included (Cowell 2005; Rossebø
2008; Chan 2010; Van der Linde 2011) and the participants were
individually randomised into treatment groups. The result of the
intervention was evaluated and analysed for each outcome in this
review.
Dealing with missing data
We contacted the study authors to clarify and recover missing
data. Only assessable data were considered in this review and the
impact of missing data are addressed in the Discussion section of
this review.
Assessment of heterogeneity
The presence of statistical heterogeneity was analysed using the I2
statistical test and the Chi2 test for each outcome. When no het-
erogeneity was found, we performed a fixed-effect model. When
substantial heterogeneity (I² statistic above 50%) was found, we
used the random-effects model in order to quantify the effect of
the findings and verify if they were statistically significant (Higgins
2011). The reasons for the presence of these large differences are
explored in the Discussion.
Assessment of reporting biases
We strived to include both published and unpublished studies
during the selection process; however the funnel plots and the test
of asymmetry to assess possible publication bias were not done due
to the insufficient number of trials found (less than10) (Higgins
2011).
Data synthesis
We carried out a meta-analysis of the data using the Review Man-
ager software, version 5.3 (RevMan 2014). Had there been stud-
ies with substantial heterogeneity and for which a meta-analysis
could not be made, we would have prepared a narrative synthe-
sis of the data. We used fixed-effect and random-effects models
to measure the effect size of the results. We used the fixed-effect
model when the studies did not show heterogeneity. We planned
to use the random-effects model if the studies showed substan-
tial heterogeneity (an I² statistic above 50%) (Higgins 2011). We
presented the effect size of the included studies in the forest plots
with their respective confidence intervals (CIs).
Subgroup analysis and investigation of heterogeneity
The number of included studies was insufficient to carry out sub-
group analysis (less than 10). Therefore, we were unable to eval-
uate the effectiveness of statins in the following subgroups: mild
aortic valve stenosis, moderate aortic valve stenosis and severe aor-
tic valve stenosis as we mentioned in the objective section of this
review. In future updates, we plan to conduct subgroup analyses
according to age, gender, type of statin and severity of illness, if
we have a sufficient number of eligible studies (more than 10).
Sensitivity analysis
The number of included studies was not enough to carry out sensi-
tivity analysis (less than 10). We would have used sensitivity anal-
ysis to test the robustness of any results that appeared to be based
on heterogeneous combinations of the studies. Had we included
more than 10 studies, we would have applied the sensitivity anal-
ysis including and excluding lower quality studies to assess the
robustness of the observed effects. In this analysis, we would have
considered death from cardiovascular cause as the most important
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outcome. We hope to be able to plan sensitivity analysis in future
updates if we have a sufficient number of eligible studies (more
than 10).
Overall quality of the body of evidence: ’Summary of
findings’ table
We generated a ’Summary of findings’ table using GRADEPRO
software (GRADE PRO 2011). This table evaluated the overall
quality of the body of evidence for the review outcomes using
GRADE criteria (study limitations [i.e. risk of bias] consistency of
effect, imprecision, indirectness and publication bias). The out-
comes analysed in the ’Summary of findings’ table were mean pres-
sure gradient, freedom from valve replacement, death from cardio-
vascular cause, hospitalisation for any reason, aortic jet velocity,
valve area and severe adverse events (muscle pain). The GRADE
assessments were incorporated into the reported result findings for
each outcome.
R E S U L T S
Description of studies
Results of the search
The database searches generated 946 citations and 645 after de-
duplication. The de-duplication is a tool to identify indexed arti-
cles in more than one of the databases. We found 450 citations in
the LILACS-IBECS database . We found two citations by search-
ing other resources.We identified nine eligible papers for inclusion
or exclusion screening the titles and abstracts of the 1097 records.
Of these nine papers, four were included (Cowell 2005; Rossebø
2008; Chan 2010; Chan 2011). We excluded three papers (Ditchl
2008; Chan 2011; Panahi 2013). We identified only two ongoing
trials (Schuler 2005; Kindo 2008).The flow of studies throughout
the review is presented in the PRISMA diagram in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Four randomised controlled trials (RCTs) were included in this
review (Cowell 2005; Rossebø 2008; Chan 2010; Van der Linde
2011). A total of 2360 adults with aortic valve stenosis were ran-
domised. All participants, mostly men (66%) and white, were fol-
lowed up for at least two years. Three of the studies analysed tricus-
pid aortic valve (Cowell 2005; Rossebø 2008; Chan 2010) and the
other study analysed mostly younger patients with bicuspid aortic
valve (Van der Linde 2011). Rosuvastatin was the intervention
drug of two studies (Chan 2010; Van der Linde 2011). Another
study used atorvastatin as intervention drug (Cowell 2005). Only
one study used a statin in association with other systemic drugs
to reduce cholesterol levels (simvastatin plus ezetimibe) as the in-
tervention drugs (Rossebø 2008). Two studies had participants
with other comorbidities such as hypertension, coronary heart dis-
ease, β-blocker and aspirin use, high levels of low-density lipopro-
tein (LDL) and who were current smokers (Cowell 2005; Rossebø
2008). For further information about study design, sites, follow-
up, participants, comorbidities, inclusion and exclusion criteria,
aortic valve morphology, severity of aortic valve stenosis, interven-
tion and outcomes for each of the included studies in this review
see Characteristics of included studies.
We also identified two ongoing trials (Schuler 2005; Kindo 2008).
One trial is analysing the effect of 40 mg of fluvastatin per day
in asymptomatic aortic valve stenosis. The primary outcomes of
this study are the progression of calcified aortic valve stenosis mea-
sured by transthoracic echocardiography (mean pressure gradient,
valve area and aortic jet velocity) and catheterisation (peak-to-
peak gradient, left ventricular function and compliance) (Schuler
2005).The recruitment status of this study is unknown as the au-
thors have not updated it. Another trial is analysing the effect 80
mg of atorvastatin per day in surgical aortic valve stenosis and is
currently recruiting participants. The primary outcomes of this
study are changes on inflammatory markers after aortic valve re-
placement and changes in left ventricular mass (Kindo 2008). For
more details, see Characteristics of ongoing studies.
No studies are awaiting classification.
Excluded studies
Three of the nine eligible studies were excluded after full-text read-
ing (Ditchl 2008; Chan 2011; Panahi 2013). For more details,
see Characteristics of excluded studies. The main reason to ex-
clude these studies was the type of design (a sub-study of AS-
TRONOMER trial) (Chan 2011), methodological flaws and high
risk of bias (Ditchl 2008; Panahi 2013).
Risk of bias in included studies
We assessed the risk of bias in the included studies as ’low’, ’high’
or ’unclear’. For more details, see below Figure 2 , Figure 3 and
Characteristics of included studies section.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
Three studies mentioned the method of sequence generation and
they were considered as low risk of bias (Cowell 2005; Chan 2010;
Van der Linde 2011). Two of these studies used a computer pro-
gram which did not have access to the rest of the data (Chan 2010;
Van der Linde 2011). One of these studies used a minimisation
technique with a computer program (Cowell 2005). One study
did not mention how the random sequence generation was made
and it was considered as having an unclear risk of bias (Rossebø
2008).
Allocation concealment
Three studies were considered as low risk of bias for allocation
concealment (Cowell 2005; Chan 2010; Van der Linde 2011).
One of these studies used a randomisation number from the study
database via a secure Internet line (Chan 2010). Another study
used numbered containers (Cowell 2005) and Van der Linde 2011
used a randomisation number that was sent to the site co-ordinator
by the pharmacology department and the study medication was
sent to the participants. Rossebø 2008 did not mention how the
allocation concealment was made and it was considered as unclear
risk of bias (Rossebø 2008).
Blinding
Blinding of participants and personnel
We considered all four studies as low risk of bias for blinding of
participants and personnel (Cowell 2005; Rossebø 2008; Chan
2010; Van der Linde 2011). All four studies were reported to be
double-blind, placebo-controlled trials.
Blinding of outcome assessment
Three studies were classified as low risk of bias for blinding of
outcome assessment (Rossebø 2008; Chan 2010; Van der Linde
2011). All members of the committees of these studies who evalu-
ated the outcomes were blinded. One of the studies was classified
as unclear risk of bias because it did not mention if the investiga-
tors were blinded to evaluate the data. This paper just mentioned
what each author did in the study (Cowell 2005).
Incomplete outcome data
We considered all four studies as low risk of bias for incomplete
outcome data (Cowell 2005; Rossebø 2008; Chan 2010; Van der
Linde 2011). Withdrawn participants were well-described in each
study.
Selective reporting
We classified all four studies as low risk of bias for selective re-
porting (Cowell 2005; Rossebø 2008; Chan 2010; Van der Linde
2011). These four studies evaluated their primary and secondary
outcomes and reported the results. Three of these four studies
reported the study protocol (Cowell 2005; Rossebø 2008; Chan
2010).
Other potential sources of bias
We considered only one study as low risk of bias for other poten-
tial sources of bias (Van der Linde 2011). Three industry funded
studies were considered high risk of bias (Cowell 2005; Rossebø
2008; Chan 2010). One of the studies received funding from the
Canadian Institute of Health Research and Astra Zeneca Canada,
but Astra Zeneca had no input into the study design and anal-
ysis (Chan 2010). In another study, the drug was provided by
Pfizer which had no access to the rest of the data (Cowell 2005).
The PROCAS trial did not received funding from any organisa-
tion (Van der Linde 2011). The SEAS trial received funding from
Merck, but the scientific responsibility of the study remained with
the independent steering committee (Rossebø 2008).
Effects of interventions
See:Summary of findings for themain comparison Statin versus
Placebo for aortic valve stenosis
Primary outcomes
1. Severity of aortic valve stenosis
1.1 Mean pressure gradient
Two studies included mean pressure gradient (Rossebø 2008; Van
der Linde 2011). The mean pressure gradient did not differ in
the participants using statin compared with the participants using
placebo (mean difference (MD) -0.54, 95% confidence interval
(CI) -1.88 to 0.80; studies = 2; participants = 1935; low-quality
evidence) Analysis 1.1. There was low heterogeneity in this com-
parison (I² = 37%).
1.2 Valve area
Two studies included valve area (Chan 2010; Van der Linde 2011).
The valve area did not differ in the participants using statin com-
pared with the participants using placebo (MD -0.07, 95% CI -
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0.28 to 0.14; studies = 2; participants = 127; low-quality evidence
) Analysis 1.2 . There was low heterogeneity in this comparison
(I² = 10%).
1.3 Aortic jet velocity
Only one study included aortic jet velocity as outcome (MD -
0.06, 95% CI -0.26 to 0.14; participants = 155; study = 1; low-
quality evidence) (Cowell 2005). There were no more studies for
comparison Analysis 1.3. Heterogeneity was not applicable.
2. Freedom from valve replacement
Four studies included freedom from valve replacement (Cowell
2005; Rossebø 2008; Chan 2010; Van der Linde 2011). Free-
dom from valve replacement did not differ in the participants us-
ing statin (309/1185, 26%) compared with the participants using
placebo (330/1175, 28%) (risk ratio (RR) 0.93, 95% CI 0.81 to
1.06; studies = 4; participants = 2360; moderate-quality evidence)
Analysis 1.4. There was no substantial heterogeneity in this com-
parison (I² = 0%).
3. Death from cardiovascular cause
Three studies included death from cardiovascular cause (Cowell
2005; Rossebø 2008; Chan 2010). Death from cardiovascular
cause did not differ in the participants using statin (52/1155,
4.5 %) compared with the participants using placebo (64/ 1142,
5.6%) (RR 0.80, 95% CI 0.56 to 1.15; studies = 3; participants =
2297; low-quality evidence) Analysis 1.5.There was no substantial
heterogeneity in this comparison (I² = 0%).
Secondary Outcomes
1. Hospitalisation for any reason
Only one study included hospitalisation for any reason as out-
come (RR 0.84, 95% CI 0.39 to 1.84; participants = 155; study
= 1; very low-quality evidence) (Cowell 2005). This outcome oc-
curred in the participants using statin (10/77, 12.9%) compared
with the participants using placebo (12/ 78, 15.3%) Analysis 1.6.
There were no more studies for comparison. Heterogeneity was
not applicable.
2. Overall mortality
Studies did not report data on overall mortality as an outcome.
3. Adverse events
We evaluated a total of five adverse events that were present in
at least two studies (muscle pain, hepatic enzymes, hepatitis, gas-
trointestinal condition and creatine kinase). We considered mus-
cle pain as the main adverse event because it is the most prevalent
adverse event that can limit the use of statin.
3.1 Muscle pain
Three studies included muscle pain (Rossebø 2008; Chan 2010;
Van der Linde 2011). Muscle pain did not differ in the partici-
pants using statin (169/1107, 15.26%) compared with the par-
ticipants using placebo (184/1097, 16.77%) (RR 0.91, 95% CI
0.75 to 1.09; studies = 3; participants = 2204; moderate-quality
evidence) Analysis 1.7. There was no substantial heterogeneity in
this comparison (I² = 0%).
3.2 Hepatic enzymes elevation
Two studies included hepatic enzymes elevation (Rossebø 2008;
Chan 2010). Hepatic enzymes elevation differed in the partici-
pants using statin (24/1059, 2.26%) compared with the partici-
pants using placebo (9/1050, 0.85%) (RR 2.66, 95% CI 1.24 to
5.67; studies = 2; participants = 2109) Analysis 1.7. There was no
substantial heterogeneity in this comparison (I² = 0%).
3.3 Hepatitis
Two studies included hepatitis (Rossebø 2008; Chan 2010). Hep-
atitis did not differ in the participants using statin (7/1077, 0.64
%) comparedwith the participants usingplacebo (6/1064, 0.56%)
(RR 1.14, 95% CI 0.40 to 3.25; studies = 2; participants = 2141)
Analysis 1.7. There was low heterogeneity in this comparison (I²
= 18%).
3.4 Gastrointestinal condition, gastrointestinal serious event or gas-
trointestinal symptoms
Three studies included gastrointestinal condition, gastrointestinal
serious event or gastrointestinal symptoms respectively (Cowell
2005;Rossebø 2008;Chan 2010).Gastrointestinal condition, gas-
trointestinal serious event or gastrointestinal symptoms did not
differ in the participants using statin (318/1154, 27%) compared
with the participants using placebo (286/1142, 25%) (RR 1.10,
95% CI 0.96 to 1.25; studies = 3; participants = 2296) Analysis
1.7. There was no substantial heterogeneity in this comparison (I²
= 0%).
3.5 Creatine kinase elevation
Two studies included creatine kinase elevation (Rossebø 2008;
Chan 2010). Creatine kinase elevation did not differ in the par-
ticipants using statin (3/1059, 0.28%) compared with the partic-
ipants using placebo (4/1050, 0.38%) (RR 0.75, 95% CI 0.17 to
3.33; studies = 2; participants = 2109) Analysis 1.7. There was no
substantial heterogeneity in this comparison (I² = 0%).
4. Patient quality of life
Studies did not report data on patient quality of life as an outcome.
Overall quality of the body of evidence: ’Summary of
findings’ table
The quality of evidence of our the obtained results was very low
to moderate. For more details, see Summary of findings for the
main comparison.
D I S C U S S I O N
The general objective of this reviewwas to evaluate the effectiveness
and safety of statins in aortic valve stenosis. We evaluated the
effectiveness of statins in aortic valve stenosis through the proposed
outcomes found in the included studies. We checked the safety
of statins as an important factor for the success of the treatment
by analysing the adverse events found in the included studies.
Though we had intended to conduct a subgroup analysis (mild,
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moderate and severe aortic valve stenosis groups) to check the
effect of statins on the different subgroups, we were unable to do
so due to insufficient number of trials (less than 10). None of the
included studies reported on quality of life and overall mortality
in their outcomes.
Summary of main results
Only four randomised controlled trials from the electronic searches
were included in this review (Cowell 2005; Rossebø 2008; Chan
2010; Van der Linde 2011). A total of 2360 adults were ran-
domised (age ranged 18 to 85 years). We analysed primary and
secondary outcomes considered for this review in each included
study. We did not identify differences between the group using
statins alone or statins in association with other drugs to reduce
cholesterol levels when compared with the placebo group for the
following primary outcomes: mean pressure gradient (low-quality
evidence) Analysis 1.1, valve area (low-quality evidence) Analysis
1.2, freedom from valve replacement (moderate-quality evidence)
Analysis 1.4 and death from cardiovascular cause (low-quality ev-
idence) Analysis 1.5. We did not carry out meta-analysis to assess
aortic jet velocity as only one study included this outcome (low-
quality evidence) Analysis 1.3. For secondary outcomes, we iden-
tified differences between the group using statins alone or statins
in association with other drugs to reduce cholesterol levels when
compared with the placebo group only for the adverse events. We
analysed five adverse events, among which was muscle pain. We
considered muscle pain as the main adverse event because it is
the most prevalent adverse event that can limit the use of statin
(moderate-quality evidence) Analysis 1.7. The quality of evidence
of the obtained results for the analysed outcomes was very low to
moderate. For more details, see Summary of findings for the main
comparison. We did not carry out meta-analysis to assess other
secondary outcomes as hospitalisation for any reason (very low-
quality evidence), as only one study reported this outcome Analy-
sis 1.6. None of the four included studies evaluated the secondary
outcomes of overall mortality nor patient quality of life. We could
not find sufficient number of trials to conduct subgroup analysis
and sensitivity analysis (more than 10). The findings of this sys-
tematic review did not show that statins may be able to delay the
progression of aortic valve stenosis.
Overall completeness and applicability of
evidence
The general objective of this review was to evaluate the effective-
ness and safety of statins in aortic valve stenosis. We summarised
the studies with the best evidence available about this subject.
Considering the analysed outcomes, our results are applicable for
people suffering from aortic valve stenosis. However, we were un-
able to find enough studies in the electronic database search that
allowed us to assess all objectives of the review. All types of par-
ticipants and interventions cited in the method section were in-
vestigated in the included studies, but we could not carry out a
meta-analysis of the outcomes aortic jet velocity and hospitalisa-
tion for any reason as both outcomes were only reported in one
study (Cowell 2005). We did not find the outcomes overall mor-
tality and patient quality of life reported in the included studies.
Two studies included participants who were current smokers and
had other comorbidities such as hypertension, coronary heart dis-
ease, β-blocker and aspirin use, high levels of LDL (Cowell 2005;
Rossebø 2008). These comorbidities could have adversely affected
the analysis of the results and they require analyses of their effect
on each of these subgroups. These difficulties encountered during
the review process did not allow us to find a high-quality evidence
in our findings, but our obtained results confirm the current in-
ternational guidelines which do not recommend statins to slow
down the progression of aortic valve stenosis.
Quality of the evidence
The GRADE approach was employed to assess the quality of re-
sult findings and the GRADE profiler (GRADEPRO) allowed us
to import data from Review Manager 5.3 to create ’Summary of
findings’ tables. The quality of evidence ranged from moderate to
very low across the different outcomes, mainly due to risk of bias
and imprecise results. One of the four included studies was low
risk of bias for the following criteria: random sequence generation;
allocation concealment; blinding of participants; personnel and
outcome assessors; incomplete outcome data and selective report-
ing among other sources of bias (Van der Linde 2011). One study
had unclear risk of bias for random sequence generation and allo-
cation concealment (selection bias) (Rossebø 2008). Three stud-
ies were high risk of bias for other bias because they were indus-
try funded trials (Cowell 2005; Rossebø 2008; Chan 2010). We
could not elucidate the risk of bias for these studies even having
contacted their authors. Overall, the studies were small and had
short follow-ups (Cowell 2005; Chan 2010; Van der Linde 2011)
which may have meant a lack of rigor in their methods and may
have produced inconsistent results. Regarding the findings of the
studies, particularly the continuous outcomes of the severity of
aortic valve stenosis were not affected by dropouts. In the largest
trial (Rossebo et al, 1873 of the 2360 patients considered in the
meta-analysis), 1857 patients (99%) were followed until the end
of the study (median 52.2months) and 1693 (90%)were included
in an echocardiographic substudy (Rossebø 2008). In the Van der
Linde study, 55/63 (87%) of patients completed follow-up (Van
der Linde 2011). In Cowell 2005, 11/155 patients (7%) discon-
tinued treatment because of adverse effects and 134/155 (86.5%)
completed the echocardiographic follow-up. In Chan 2010, the
discontinuation rate was high (123/269, 45%). There were 51
cases due to adverse events, but only three patients were lost dur-
ing the follow-up. Per-protocol analysis yielded similar results to
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intention-to-treat analysis. We were unable to assess the publica-
tion bias in funnel plots due to limited number of the included
studies (less than 10). All of these considerations were taken into
account when interpreting the results of this systematic review.
Potential biases in the review process
We attempted to include all relevant studies in this review from
an electronic sensitised search. Two review authors independently
selected, collected and analysed the data in order to minimise bias.
One limitation was that we could not find sufficient studies to
perform sensitivity analysis, subgroup analysis, or to assess publi-
cation bias. Another limitation was that we could not carry out
meta-analysis to assess the secondary outcome of hospitalisation
for any reason as only one trial reported this outcome, and the
secondary outcomes of overall mortality and patient quality of life
were not reported in any of the trials.
Agreements and disagreements with other
studies or reviews
A meta-analysis published by Teo KK et al in 2011 (2344 partici-
pants) (Teo 2011) did not find differences of effect between statin
or placebo groups for similar outcomes such as aortic valve stenosis
severity, freedom from valve replacement and cardiovascular death
either. However, we analysed the safety of statins through their
adverse events in this paper. We found differences in one adverse
event between statin and placebo group: hepatic enzymes (RR
2.66, 95%CI 1.24 to 5.67; studies = 2; participants = 2109). Nev-
ertheless, a recent review demonstrated that drug-induced liver
injury statin is rare (22 cases from 1188 drug-induced liver injury
cases, eight years of follow-up) (Russo 2014).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found only four randomised controlled trials in the electronic
search which analysed the role of statins on the progression of
aortic valve stenosis. Some of these studies had limitations such
as follow-up, sample size and the randomisation process. Some
objectives of the review could not be accomplished due to the in-
sufficient number of the included studies. This also affected the
quality of our obtained results which did not show statins can de-
lay the progression of aortic valve stenosis. The quality of evidence
of the obtained results was very low to moderate. Although the
first experimental and retrospective studies found some benefit of
statins in aortic valve stenosis in the past decade, European and
USA guidelines do not recommend this intervention (Vahanian
2012; Nishimura 2014). Our findings are consistent with these
guidelines. However, we believe this issue is not over, mainly be-
cause the available evidence is based on studies which have limi-
tations such as follow-up, randomisation process, sample size and
very elderly participants with many comorbidities.
Implications for research
We believe the research for a clinical treatment for aortic valve
stenosis should continue to be encouraged. The current option
for the treatment of aortic valve stenosis is still aortic replace-
ment surgery or transcatheter aortic-valve implantation (TAVI).
However, because this medical condition has a long progression,
when patients are submitted to these procedures they are symp-
tomatic, have severe aortic valve stenosis, and high mortality. For
future clinical treatment research on aortic valve stenosis, an al-
ternative might be to broaden the pathophysiology knowledge of
this disease and search for other risk factors such as accumulation
of calcium, heredity, diabetes, vitamin D, inflammation, oxida-
tive stress, hypertension, among others that could contribute to
its development. A suggestion regarding these risk factors, for ex-
ample, could be to compare individuals suffering from hyperten-
sion and diabetes with individuals suffering only from diabetes. In
this comparison, it could be assessed if the drug for hypertension
would prevent the development of aortic valve stenosis. Searching
for such risk factors for aortic valve stenosis might promote future
clinical trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chan 2010
Methods Randomised, double-blind, placebo-controlled trial.
Participants Men and women between 18 and 82 years of age (mean of age = 58 years). Total
participants = 269 (from 23 Canadian Centres) with asymptomatic mild aortic valve
stenosis defined by maximum aortic valve velocity between 2.5 and 4.0 m/s. Participants
were followed for a minimum of 3 years to a maximum of 5 years (median follow-up =
3.5 years)
Baseline Characteristics of Participants:
Men = 60.5% (rosuvastatin group) and 63% (placebo group).
Tricuspid Aortic Valve = 29.1% (rosuvastatin group) and 34.1% (placebo group)
Bicuspid Aortic Valve = 53.7% (rosuvastatin group) and 45.2% (placebo group)
Uncertain Aortic Valve Morphology = 17.2% (rosuvastatin group) and 20.7% (placebo
group)
Mean Pressure Gradient, mean (± SD) mmHg = 22.5 (± 7.6) (rosuvastatin group) and
23.1(± 7.6) (placebo group)
Peak Pressure Gradient, mean (± SD) mmHg = 40.8 (± 11.1) (rosuvastatin group) and
41.6 (± 10.9) (placebo group)
Aortic Valve Area, mean (± SD) cm² = 1.49 (± 0.71) (rosuvastatin group) and 1.56 (±
0.70) (placebo group)
Peak AS Velocity, mean (± SD) m/s = 3.16 (± 0.42) (rosuvastatin group) and 3.19 (± 0.
42) (placebo group)
LDL value (± SD) = 3.18 mmol/L (± 0.63 SD) (rosuvastatin group) and 3.12 mmol/L
(± 0.74 SD) (placebo group)
Systolic blood pressure, mean (± SD) mmHg = 128.8 (± 15.67) (rosuvastatin group) and
128.4 (± 15.94) (placebo group)
Diastolic blood pressure, mean (± SD) = 76.5 (± 10.04) (rosuvastatin group) and 75.9
(± 10.92) (placebo group)
Most of the participants were white.
Interventions Rosuvastatin 40 mg daily (n = 134) or matching placebo (n = 135). Participants were
randomised in 1:1 fashion in blocks of 4
Outcomes Primary Outcome: Transvalvular aortic stenosis gradient and aortic valve area measured
by Doppler echocardiography
Secondary Outcome: Aortic valve replacement and cardiovascular death
Notes The trial was supported by the Canadian Institute of Health Research with additional
support from Astra Zeneca Canada Inc, but Astra Zeneca Canada had no input into the
study design and data analysis
Risk of bias
Bias Authors’ judgement Support for judgement
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Chan 2010 (Continued)
Random sequence generation (selection
bias)
Low risk Rosuvastatin and placebo groups were ran-
domised using a computer program at As-
tra ZenecaCanada Inc, which has no access
to the rest of the data
Allocation concealment (selection bias) Low risk A randomisation number was from the
study database via a secure Internet line
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, site co-ordinators, investiga-
tors and statisticians were all blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The members of Committee who evalu-
ated all outcomes and serious adverse events
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants who withdrew from the study
were well-described and all the randomised
patients were evaluated for outcomes
Selective reporting (reporting bias) Low risk Study protocol is available and is well-de-
scribed.
Other bias High risk The study received funding from theCana-
dian Institute of Health Research and Astra
Zeneca Canada, but Astra Zeneca Canada
had no input into the study design and a
data analysis
Cowell 2005
Methods Randomised, double-blind, placebo-controlled trial.
Participants 155 participants were randomised (older than 18 years of age, mean of age = 68 years)
with calcific aortic stenosis, an aortic jet velocity of at least 2.5 m per second and aortic
valve calcification measured by Doppler Echocardiography. Participants were followed
between 7 and 36 months (median of 25 months)
Baseline Characteristics of Participants:
Men = 68% (atorvastatin group) and 72% (placebo group).
Tricuspid Aortic Valve = 96% (atorvastatin group) and 97% (placebo group)
Bicuspid Aortic Valve = 4% (atorvastatin group) and 3% (placebo group)
Peak Pressure Gradient, mean (± SD) mmHg = 47.8 (± 17.4) (atorvastatin group) and
49.5 (± 19.5) (placebo group)
Aortic Valve Area, mean (± SD) cm² = 1.03 (± 0.40) (atorvastatin group) and 1.02 (± 0.
41) (placebo group)
Aortic Jet Velocity, mean (± SD) m/s = 3.39 (± 0.62) (atorvastatin group) and 3.45 (±
0.67) (placebo group)
Most of the participants had hypertension and used aspirin.
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Cowell 2005 (Continued)
Current Smoker = 27% (atorvastatin group) and 28% (placebo group)
Coronary heart disease = 23% (atorvastatin group) and 26% (placebo group)
β-blocker use = 27% (atorvastatin group) and 34% (placebo group)
LDL value (± SD) = 137 mg/dL (± 34) (atorvastatin group) and 133 mg/dL (± 30)
(placebo group)
Interventions Atorvastatin 80 mg daily (n = 77) or matching placebo (n = 78)
Outcomes Primary Outcome: Progression of aortic valve stenosis by changes in aortic jet velocity
on doppler echocardiography and progression of valvular calcification by computer to-
mography
Secondary Outcome: Aortic valve replacement, death from any cause, death from car-
diovascular causes, hospitalisation for severe aortic valve, hospitalisation for any cause
and hospitalisation for cardiovascular causes
Notes The study drug was provided by Pfizer, which has no access to the rest of the data.The
authors received support from Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Atorvastatin and placebo groups were ran-
domised using a minimisation technique
with a dedicated, locked computer pro-
gram (Edinburgh University)
Allocation concealment (selection bias) Low risk Numbered containers were used.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk There was no information to say that the
investigators were blinded to evaluate the
data.The paper just mentioned what each
author did in the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of missing values was well-
balanced between groups
Selective reporting (reporting bias) Low risk Study protocol is available and well-de-
scribed.
Other bias High risk The study drug was provided by Pfizer,
which had no access to the rest of the data.
The authors received support from Pfizer
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Rossebø 2008
Methods Randomised, double-blind, placebo-controlled trial.
Participants Men and women between the ages of 45 and 85 years (mean of age = 67.9) who had
asymptomatic, mild to moderate aortic valve stenosis, as assessed on echocardiography,
with peak aortic jet velocity of 2.5 to 4 m/s. 1873 participants were randomised. The
minimum follow-up was 4 years (median = 52.2 months)
Baseline Characteristics of Participants:
Men = 61.5% (simvastatin plus ezetimibe group) and 61.2 % (placebo group)
BicuspidAortic Valve = 5% (simvastatin plus ezetimibe group) and 6.3% (placebo group)
Peak Pressure Gradient, mean (± SD) mmHg = 39.3 (± 13.9) (simvastatin plus ezetimibe
group) and 39.6 (± 8.7) (simvastatin plus ezetimibe group)
Mean Pressure Gradient, mean (± SD) mmHg = 22.7 (± 8.8) (simvastatin plus ezetimibe
group) and 23 (± 13.8) (simvastatin plus ezetimibe group)
Aortic Valve Area, mean (± SD) cm² = 1.29 (± 0.48) (simvastatin plus ezetimibe group)
and 1.27 (± 0.46) (placebo group)
Peak Aortic Jet Velocity, mean (± SD) m/s = 3.09 (± 0.55) (simvastatin plus ezetimibe
arm) and 3.10 (± 0.54) (placebo arm)
Most of the participants were white and had hypertension.
Former smoking = 37% (simvastatin plus ezetimibe group) and 35 %(placebo group)
Neoplasm = 11% (simvastatin plus ezetimibe group ) and 8.4% (placebo group)
β-blocker and Aspirin use: 28% (simvastatin plus ezetimibe group) and 25% (placebo
group)
Calcium antagonist use = 17% (simvastatin plus ezetimibe group) and 16% (placebo
group)
Diuretic (including spironolactone) = 22% (simvastatin plus ezetimibe group) and 28%
(placebo group)
The mean of left ventricular ejection fraction was 66% for both groups
LDL value, (± SD) = 139 mg/dL (± 35) (simvastatin plus ezetimibe group) and 140 mg/
dL (±36) (placebo group)
Interventions Simvastatin (40 mg) plus ezetimibe (10 mg) (n = 944) or matching placebo (n = 929)
Outcomes Primary outcome: death from cardiovascular causes, aortic valve replacement, congestive
heart failure, non-fatal myocardial infarction, hospitalisation for unstable angina, coro-
nary artery bypass grafting, percutaneous coronary intervention, or non-haemorrhagic
stroke
Secondary outcome: All primary outcomes above and progression of aortic stenosis as
seen on echocardiography and safety of the study drugs
Notes 173 study sites in seven European countries.
The authors received support from Merck.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Does not mention how the random se-
quence generation was carried out
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Rossebø 2008 (Continued)
Allocation concealment (selection bias) Unclear risk Does not mention how the allocation con-
cealment was carried out
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigatorswere blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The Committee members who evaluated
all outcomes were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of withdrawals were reported.
Selective reporting (reporting bias) Low risk Study protocol is available and well-de-
scribed.
Other bias High risk The study was provided by Merck, but the
scientific responsibility remained with the
independent steering committee
Van der Linde 2011
Methods Randomised, double-blind, placebo-controlled trial.
Participants Women andmenbetween18 and45years of age (meanof age 33 years). Total participants
= 242; 63 randomised with congenital aortic valve stenosis and peak aortic valve velocity
of 2.5 m/s. The median follow-up was 2.4 years
Baseline Characteristics of Participants:
Men: 70% (rosuvastatin group) and 73% (placebo group).
Bicuspid Valve: 93% (rosuvastatin group) and 88% (placebo group)
Tricuspid Valve: 7 % (rosuvastatin group) and 12% (placebo group)
Mean Pressure Gradient, mean (± SD) mmHg = 27 (± 10) (rosuvastatin group) and 32
(± 17) (placebo group)
Peak Pressure Gradient, mean (± SD) mmHg = 48 (± 18) (rosuvastatin group) and 56
(± 28) (placebo group)
Aortic Valve Area, mean (± SD) cm² = 1.3 (± 0.4) (rosuvastatin group) and 1.3 (± 0.5)
(placebo group)
Peak AS Velocity, mean (± SD) m/s = 3.4 (± 0.7) (rosuvastatin group) and 3.6 (± 0.9)
(placebo group)
Most of the participants had a previous intervention (surgical valvulotomy or balloon
valvuloplasty) and none or a grade 1 of aortic regurgitation
Systolic blood pressure, mean (± SD) mmHg = 129 (± 16) (rosuvastatin group) and 131
(±16) (placebo group)
Diastolic blood pressure, mean (± SD) mmHg = 76 (± 10) (rosuvastatin group) and 78
(± 10) (placebo group)
Aortic valve calcium = 40% (rosuvastatin group) and 36% (placebo group)
Left ventricular hypertrophy = 20% (rosuvastatin group) and 33%(placebo group)
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Van der Linde 2011 (Continued)
LDL value, (± SD) = 106 mg/dL (± 31) (rosuvastatin group) and 104 mg/dL (± 35)
(placebo group)
Interventions Rosuvastatin 10 mg (n = 30) or matching placebo (n = 33).
Outcomes Primary outcome: progression of peak aortic valve velocity.
Secondary outcome: temporal changes in the left ventricular mass, ascending aortic
diameter and N-terminal pro-brain natriuretic peptide
Notes Study Site: 6 tertiary referral centres for congenital heart disease in The Netherlands and
Belgium
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Rosuvastatin and placebo groups were ran-
domised using a computer program at the
Erasmus Medical University Center phar-
macology department, which had no access
to the rest of data
Allocation concealment (selection bias) Low risk A randomisation number was sent by phar-
macology department to the site co-ordi-
nator and the study medication to the par-
ticipants. The participants were unaware of
the treatment assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients, physicians and investigators were
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The investigators that evaluated all out-
comes were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Patients who withdrew from the study were
well-described all the randomised patients
were evaluated
Selective reporting (reporting bias) Low risk Study protocol is not available, but all data
were properly reported
Other bias Low risk There was no other bias. The study did not
received support from any organisations
LDL: low-density lipoprotein
SD: standard deviation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chan 2011 Sub study of ASTRONOMER trial.
Ditchl 2008 Study with methodological flaws and high risk of bias.
Panahi 2013 Study with methodological flaws and high risk of bias.
Characteristics of ongoing studies [ordered by study ID]
Kindo 2008
Trial name or title Interest of statin in surgical aortic stenosis: frommyocardial preconditioning to ventricular reverse remodeling
Methods Randomised controlled trial.
Allocation: Randomised.
Endpoint Classification: Efficacy study.
Intervention Model: Parallel assignment.
Masking: Single-blind (participant).
Primary Purpose: Treatment.
Phase: 3.
Participants Inclusion Criteria:
1. Age > or = 70 years and < 80 years.
2. Severe aortic valve stenosis.
3. Indication for aortic valve replacement by bioprosthesis.
4. Ejection fraction > or = 50%.
5. Without treatment with statin and no renal failure.
6. Informed consent signed.
Exclusion Criteria:
1. Ischemic heart disease.
2. Concomitant surgery to aortic valve replacement.
3. Emergency surgery and known intolerance for statin.
4. Pregnant woman.
Interventions Atorvastatin 80 mg per day.
Outcomes Primary outcomes:
Phase I: To study changes on inflammatory markers after aortic valve replacement
Phase II: To study changes in left ventricular mass at the end of the study (12 months). [ Time Frame: 1 year
] [ Designated as safety issue: No ]
Secondary outcomes:
Phase I: To study changes on mitochondrial function, reactive oxygen species, and perioperative systolic and
diastolic functions
Phase II: To study changes on clinical status, systolic and diastolic functions during the one year follow-up. [
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Kindo 2008 (Continued)
Time Frame: 1 year ] [Designated as safety issue: No ]
Starting date December 2008.
Contact information Michel KINDO, MD.
University Hospital, Strasbourg.
France.
E-mail: michel.kindo@chru-strasbourg.fr.
Notes ClinicalTrials.gov Identifier: NCT00811330.
This study is currently recruiting participants.
First received: December 17, 2008.
Last updated: June 18, 2015.
Last verified: June 2015.
Schuler 2005
Trial name or title Statin therapy in asymptomatic aortic stenosis
Methods Randomised controlled trial.
Allocation: Randomised.
Endpoint Classification: Efficacy study.
Intervention Model: Single-group assignment.
Masking: Double-blind (participant, investigator, outcomes assessor)
Primary Purpose: Treatment.
Phase: 2.
Participants Inclusion Criteria:
1. Age 21 years to 80 years.
2. Gender: both.
3. Mild to moderate aortic stenosis.
4. No symptoms caused by aortic stenosis.
5. Written informed consent to participate in the study.
6. Aortic valve leaflet thickening with reduced systolic opening
7. Reduced aortic valve area > 0.8 cm2 and < 1.5 cm2.
8. Maximum aortic jet velocity at rest > 2.5 m/s.
Exclusion Criteria:
1. Symptoms caused by aortic stenosis.
2. Aortic valve area < 0.7 cm2.
3. Severe aortic regurgitation.
4. Reduced left ventricular ejection fraction (< 50%).
5. Any valve disease with indication for surgery.
6. Coronary artery disease.
7. Therapy refractory arterial hypertension.
8. Comorbid noncardiac diseases or other reasons which make a regular follow-up impossible
9. Other indication for treatment with statins.
10. Women of childbearing potential not using the contraception method(s) specified in this study (specify)
, as well as women who are breastfeeding
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Schuler 2005 (Continued)
11. Known sensitivity to study drug(s) or class of study drug(s)
12. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in
the study (specify as required)
13. Use of any other investigational agent in the last 30 days
Interventions 40 mg fluvastatin daily.
Outcomes Primary outcomes:
1. Progression of calcified aortic stenosis measured by: [ Time Frame: 24 months ] [ Designated as safety issue:
No ]
2. Transthoracic echocardiography (peak max/ mean, velocity max and aortic valve area) [ Time Frame: 24
months ] [ Designated as safety issue: No ]
3. Catheterisation (peak to peak gradient, left ventricular function and compliance) [ Time Frame: 24 months
] [ Designated as safety issue: No ]
Secondary outcomes:
Number of cardiovascular events [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Starting date January 2003.
Contact information Claudia Walther, MD.
University of Leipzig.
Germany.
Telephone: xx49-341-8651428.
E-mail: waltherc@medizin.uni-leipzig.de.
Notes ClinicalTrials.gov Identifier: NCT00176410.
The recruitment status of this study is unknown because the information has not been verified recently
First received: September 13, 2005.
Last updated: January 13, 2010.
Last verified: September 2006.
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D A T A A N D A N A L Y S E S
Comparison 1. Statin versus Placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean pressure gradient 2 1935 Mean Difference (IV, Fixed, 95% CI) -0.54 [-1.88, 0.80]
2 Valve area 2 127 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.28, 0.14]
3 Aortic jet velocity 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Freedom from valve replacement 4 2360 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.81, 1.06]
5 Death from cardiovascular cause 3 2297 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.56, 1.15]
6 Hospitalisation for any reason 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7 Severe adverse events 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Muscle pain 3 2204 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.75, 1.09]
7.2 Hepatic enzymes elevation 2 2109 Risk Ratio (M-H, Fixed, 95% CI) 2.66 [1.24, 5.67]
7.3 Hepatitis 2 2141 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.40, 3.25]
7.4 Gastrointestinal condition 3 2296 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.96, 1.25]
7.5 Creatine kinase 2 2109 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.17, 3.33]
A D D I T I O N A L T A B L E S
Table 1. Echocardiografic criteria for aortic valve stenosis (Vahanian 2012; Nishimura 2014)
Mild
Aortic stenosis
Moderate
Aortic stenosis
Severe
Aortic stenosis
Valve area 1.5 cm² 1.0 to 1.5 cm² < 1.0 cm²
Mean pressure
gradient
< 20 mmHg 20 to 39 mmHg > 40 mmHg
Aortic jet velocity < 2.0 to 2.9 m
per second
3.0 to 3.9 m
per second
> 4.0 m
per second
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We included GRADE to assess the quality evidence of the review (GRADE PRO 2011).
Two new co-authors were added (Cristiane Rufino Macedo and Jonathan Nyong).
We excluded two studies on the basis of high risk of bias and methodological flaws as instructed by the editorial staff. The low number
of patients in these trials suggests that no significant change could occur in meta-analysis results.
In the protocol of this review, we planned to assess if the effect of the treatment varies according to different populations (age, gender
and severity of illness) or to characteristics of the intervention (type of statin). However, the numbers of the included studies identified
by the electronic search were not enough to carry out subgroup analysis. We also did not conduct the planned sensitivity analysis
to assess the robustness of the observed effects due to insufficient number of trials. Although we did not specify the number in the
protocol, we consider that at least 10 included studies are required to carry out subgroup and sensitivity analyses. In future updates of
this review, we intend to carry out subgroup analysis by age, gender, type of statin and severity of Illness (mild, moderate and severe
aortic valve stenosis) and sensitivity analysis, provided we have more than 10 eligible studies.
We planned to calculate NNT (number needed to treat for an additional beneficial outcome (NNTB) or the number needed to
treat for an additional harmful outcome (NNTH)) (Higgins 2011) in the protocol, but it was not possible because we did not find
any significant difference between the participants who received statin compared with the participants who received placebo for the
following outcomes: mean pressure gradient, freedom from valve replacement, death from cardiovascular cause and valve area.
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